{"id":745259,"date":"2015-02-23T07:00:00","date_gmt":"2015-02-23T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\/"},"modified":"2025-11-07T01:25:22","modified_gmt":"2025-11-07T06:25:22","slug":"ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\/","title":{"rendered":"NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics"},"content":{"rendered":"<p class=\"bwalignc\">       Partnership Combines NGM\u2019s Unique Biology-focused Research Platform        with Merck\u2019s Late-stage Clinical and Commercialization Strengths to Discover        Medicines for Serious Diseases     <\/p>\n<p class=\"bwpindent\">\n      NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and<br \/>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced they have entered into a multi-year collaboration to<br \/>\n      research, discover, develop and commercialize novel biologic therapies<br \/>\n      across a wide range of therapeutic areas. This agreement will become<br \/>\n      effective upon the expiration of the waiting period under the<br \/>\n      Hart-Scott-Rodino Antitrust Improvements Act.\n    <\/p>\n<p class=\"bwpindent\">\n      \u201cWe are very pleased to establish this alliance with Merck, which will<br \/>\n      be transformational for NGM, providing us with the resources and<br \/>\n      flexibility to pursue our ambitious research and development goals while<br \/>\n      preserving our unique drug discovery culture,\u201d said William J. Rieflin,<br \/>\n      Chief Executive Officer of NGM. \u201cWe look forward to working with Merck<br \/>\n      to generate a robust pipeline of therapies with the potential to make a<br \/>\n      significant difference in the lives of patients.\u201d\n    <\/p>\n<p class=\"bwpindent\">\n      \u201cNGM has developed a uniquely powerful research program that has<br \/>\n      permitted identification of novel, and quite consequential, pathways for<br \/>\n      metabolic regulation,\u201d said Dr. Roger M. Perlmutter, President of Merck<br \/>\n      Research Laboratories. \u201cThrough this new collaboration, we hope to apply<br \/>\n      Merck\u2019s well-established translational capabilities to advance<br \/>\n      innovative biologics that address the needs of patients suffering from<br \/>\n      diabetes, metabolic dysregulation, and malignancy.\u201d\n    <\/p>\n<p class=\"bwpindent\">\n      The collaboration includes multiple drug candidates currently in<br \/>\n      preclinical development at NGM, including NP201, which is being<br \/>\n      evaluated for the treatment of diabetes, obesity and nonalcoholic<br \/>\n      steatohepatitis (NASH). NGM will lead the research and development of<br \/>\n      the existing preclinical candidates and have the autonomy to identify<br \/>\n      and pursue other discovery stage programs at its discretion. Merck will<br \/>\n      have the option to license all resulting NGM programs following human<br \/>\n      proof of concept trials. If Merck exercises this option, Merck will lead<br \/>\n      global product development and commercialization for the resulting<br \/>\n      products, if approved.\n    <\/p>\n<p class=\"bwpindent\">\n      Under the terms of the agreement, Merck will make an upfront payment to<br \/>\n      NGM of $94 million and will purchase a 15 percent equity stake in NGM<br \/>\n      for $106 million at a price per share that represents a 20 percent<br \/>\n      premium to NGM\u2019s most recent financing. Merck will commit up to $250<br \/>\n      million to fund all of NGM\u2019s efforts under the initial five-year term of<br \/>\n      the collaboration, with the potential for additional funding if certain<br \/>\n      conditions are met.\n    <\/p>\n<p class=\"bwpindent\">\n      Prior to Merck initiating a Phase 3 study for a licensed program, NGM<br \/>\n      may elect to either receive milestone and royalty payments or, in<br \/>\n      certain cases, to co-fund development and participate in a global cost<br \/>\n      and revenue share arrangement of up to 50 percent. The agreement also<br \/>\n      provides NGM with the option to participate in the co-promotion of any<br \/>\n      co-funded program in the United States. Merck will have the option to<br \/>\n      extend the research agreement for two additional two-year terms.\n    <\/p>\n<p class=\"bwpindent\">\n      \u201cThis collaboration brings together our biology-driven research and<br \/>\n      development product platform with Merck\u2019s late-stage development and<br \/>\n      commercialization expertise, while also enabling NGM to explore exciting<br \/>\n      new drug targets,\u201d commented Dr. Jin-Long Chen, Founder and Chief<br \/>\n      Scientific Officer of NGM. \u201cBoth companies&#8217; commitment to scientific<br \/>\n      excellence and willingness to creatively combine our strengths was key<br \/>\n      to establishing this relationship.&#8221;\n    <\/p>\n<p class=\"bwpindent\">\n      NGM\u2019s lead program, NGM282, currently in clinical development for<br \/>\n      primary biliary cirrhosis (PBC) and NASH, as well as programs that are<br \/>\n      the focus of NGM\u2019s pre-existing collaboration agreements, are not<br \/>\n      subject to the option under the Merck collaboration.\n    <\/p>\n<p>\n      <b>NGM Conference Call Information<\/b>\n    <\/p>\n<p class=\"bwpindent\">\n      NGM will host a conference call and live audio webcast today at 9:30<br \/>\n      a.m. ET. To participate in the conference call, please dial<br \/>\n      1-877-930-8423 (domestic) or 1-253-642-1003 (international) and refer to<br \/>\n      conference ID 89756919. The live webcast can be accessed via <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fedge.media-server.com%2Fm%2Fp%2Fx7uj3857&amp;esheet=51044798&amp;newsitemid=20150223005260&amp;lan=en-US&amp;anchor=http%3A%2F%2Fedge.media-server.com%2Fm%2Fp%2Fx7uj3857&amp;index=1&amp;md5=2ed6a90d5575d5c7d1bd27cdd1988ea8\" rel=\"nofollow\">http:\/\/edge.media-server.com\/m\/p\/x7uj3857<\/a>.\n    <\/p>\n<p class=\"bwpindent\">\n      The archived webcast will be available on the Company\u2019s website, <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ngmbio.com&amp;esheet=51044798&amp;newsitemid=20150223005260&amp;lan=en-US&amp;anchor=www.ngmbio.com&amp;index=2&amp;md5=a3a09deccf74804fc77764e262cdbe95\" rel=\"nofollow\">www.ngmbio.com<\/a>,<br \/>\n      beginning approximately two hours after the event.\n    <\/p>\n<p>\n      <b>About NGM Biopharmaceuticals<\/b>\n    <\/p>\n<p class=\"bwpindent\">\n      NGM Biopharmaceuticals is a private biopharmaceutical company using a<br \/>\n      biology-centric approach to create novel biologics for the treatment of<br \/>\n      a broad spectrum of life-threatening diseases. NGM\u2019s lead compound,<br \/>\n      NGM282, is in a Phase 2b study for the treatment of PBC. NGM282 has<br \/>\n      received Orphan Drug Designations in the U.S. and EU, and has been<br \/>\n      granted Fast Track Designation for PBC by the U.S. Food and Drug<br \/>\n      Administration. NGM has established collaborations with Merck,<br \/>\n      MedImmune, Daiichi Sankyo and JDRF. NGM is financed by The Column Group,<br \/>\n      Prospect Ventures, Rho Ventures, Tichenor Ventures, Topspin Ventures and<br \/>\n      other leading investors around the world. For more information, please<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ngmbio.com&amp;esheet=51044798&amp;newsitemid=20150223005260&amp;lan=en-US&amp;anchor=www.ngmbio.com&amp;index=3&amp;md5=e03649be662c88419630a4a8b505ab93\" rel=\"nofollow\">www.ngmbio.com<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p class=\"bwpindent\">\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51044798&amp;newsitemid=20150223005260&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=4&amp;md5=63b10c90dfb41536adef3f11ab557741\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51044798&amp;newsitemid=20150223005260&amp;lan=en-US&amp;anchor=Twitter&amp;index=5&amp;md5=c5a764c0cab335c29dd27c02dad0387d\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51044798&amp;newsitemid=20150223005260&amp;lan=en-US&amp;anchor=Facebook&amp;index=6&amp;md5=579577037928da6f1e36e873ebf3dffb\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51044798&amp;newsitemid=20150223005260&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=e7b9f7f1d49b0cb8f31b038964d04a56\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p class=\"bwpindent\">\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the U.S. Private Securities<br \/>\n      Litigation Reform Act of 1995. These statements are based upon the<br \/>\n      current beliefs and expectations of Merck\u2019s management and are subject<br \/>\n      to significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p class=\"bwpindent\">\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p class=\"bwpindent\">\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51044798&amp;newsitemid=20150223005260&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=895081adbce3cc0af1745b81e5d12c1a\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p class=\"bwalignc\">\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150223005260r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">Photos\/Multimedia Gallery Available: <\/span><span id=\"mmgallerylink-link\"><a href=\"http:\/\/www.businesswire.com\/multimedia\/home\/20150223005260\/en\/\" rel=\"nofollow\">http:\/\/www.businesswire.com\/multimedia\/home\/20150223005260\/en\/<\/a><\/span><\/p>\n<p>       Merck<br \/>Media Relations:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Kim        Hamilton, 908-740-1863<br \/>or<br \/>Investor Relations:<br \/>Justin        Holko, 908-740-1879<br \/>or<br \/>NGM Biopharmaceuticals<br \/>Media        Relations:<br \/>Tony Plohoros, 908-940-0135<br \/>6 Degrees<br \/><a href=\"mailto:tplohoros@6degreespr.com\">tplohoros@6degreespr.com<\/a><br \/>or<br \/>Investor        Relations:<br \/>Beth DelGiacco, 212-362-1200<br \/>Stern Investor        Relations<br \/><a href=\"mailto:beth@sternir.com\">beth@sternir.com<\/a>     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Partnership Combines NGM\u2019s Unique Biology-focused Research Platform with Merck\u2019s Late-stage Clinical and Commercialization Strengths to Discover Medicines for Serious Diseases NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. \u201cWe are very pleased to establish this alliance with Merck, which will be transformational for NGM, providing us with the resources and flexibility to pursue our ambitious research and development goals while preserving our unique drug discovery culture,\u201d said William J. Rieflin, Chief Executive Officer of NGM. \u201cWe look forward to working with Merck to generate<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745259","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Partnership Combines NGM\u2019s Unique Biology-focused Research Platform with Merck\u2019s Late-stage Clinical and Commercialization Strengths to Discover Medicines for Serious Diseases NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. \u201cWe are very pleased to establish this alliance with Merck, which will be transformational for NGM, providing us with the resources and flexibility to pursue our ambitious research and development goals while preserving our unique drug discovery culture,\u201d said William J. Rieflin, Chief Executive Officer of NGM. \u201cWe look forward to working with Merck to generate\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:22+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150223005260r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\\\/\",\"name\":\"NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150223005260r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2015-02-23T07:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150223005260r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20150223005260r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics - Merck.com","og_description":"Partnership Combines NGM\u2019s Unique Biology-focused Research Platform with Merck\u2019s Late-stage Clinical and Commercialization Strengths to Discover Medicines for Serious Diseases NGM Biopharmaceuticals, Inc., a privately-held biotechnology company and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced they have entered into a multi-year collaboration to research, discover, develop and commercialize novel biologic therapies across a wide range of therapeutic areas. This agreement will become effective upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. \u201cWe are very pleased to establish this alliance with Merck, which will be transformational for NGM, providing us with the resources and flexibility to pursue our ambitious research and development goals while preserving our unique drug discovery culture,\u201d said William J. Rieflin, Chief Executive Officer of NGM. \u201cWe look forward to working with Merck to generate","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:22+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150223005260r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\/","name":"NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150223005260r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","datePublished":"2015-02-23T07:00:00+00:00","dateModified":"2025-11-07T06:25:22+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150223005260r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150223005260r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/ngm-and-merck-announce-broad-strategic-collaboration-to-discover-develop-and-commercialize-novel-biologic-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"7da73fda-e0f5-482f-8ae5-04890756a2f1","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2015\/02\/1\/merck_logo.jpg","size":"21167","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2015\/02\/1\/NGM_Logo-5B1-5D.jpg","size":"25692","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/NGM-and-Merck-Announce-Broad-Strategic-Collaboration-to-Discover-Develop-and-Commercialize-Novel-Biologic-Therapeutics-2015.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745259","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745259\/revisions"}],"predecessor-version":[{"id":3674683,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745259\/revisions\/3674683"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745259"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745259"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}